Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Exercise training for cardiovascular prevention in patients with cancer.

European heart journal·2026
Same author

One echocardiographic or hemodynamic parameter improves mortality prediction by the ESC/ERS four-strata model: a flexible approach to follow-up risk stratification in pulmonary arterial hypertension.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Preoperative cardiovascular evaluation in patients with cancer.

Frontiers in cardiovascular medicine·2026
Same author

Seeing the Unseen: Deep Learning and the Pre-Therapy Cardiac Phenotype in Cardiotoxicity.

JACC. Cardiovascular imaging·2026
Same author

Myeloid DRP1 Sulfenylation Drives Reparative Macrophage Polarization and Neovascularization in Ischemic Muscle.

Antioxidants (Basel, Switzerland)·2026
Same author

Interpreting Pulmonary Hypertension Beyond Single Cells.

Arteriosclerosis, thrombosis, and vascular biology·2026

相关实验视频

Updated: Jan 7, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K

SHP2:一种氧敏感调节剂,将免疫检查点抑制剂治疗与癌症治疗和血管风险联系起来.

Silvia Fernanda López Moreno1,2, Stefania Assunto Lenz1,2, Bernardo Casso-Chapa1,2

  • 1Department of Cardiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1057, Houston, TX 77030, USA.

Antioxidants (Basel, Switzerland)
|December 30, 2025
PubMed
概括

含有蛋白质氨酸酸酶2 (SHP2) 的Src同质2-域在免疫和血管系统中起着双重作用. 了解其上下文特异性信号对于癌症治疗和控制免疫检查点抑制剂引起的心血管并发症至关重要.

关键词:
ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI IC1 ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI IC1 IC1 IC1 IC1 IC1 IC2 IC1 IC2 IC2 IC2 IC1 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2在PD-1中使用PD-1.在PD-L1中.SHP2 氨酸酸酶为氨酸酸酶的一种.和心血管疾病.癌症 癌症 癌症 癌症 癌症氧化应激是一种氧化应激.脚手架中的蛋白质.

更多相关视频

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.6K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.0K

相关实验视频

Last Updated: Jan 7, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.6K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.0K

科学领域:

  • 生物化学 生物化学
  • 免疫学 免疫学 免疫学
  • 心血管生物学 心血管生物学

背景情况:

  • 由PTPN11编码的含有蛋白质氨酸酸酶2 (SHP2) 的Src同质2-域,是PD-1/PD-L1信号传递的关键媒介.
  • SHP2的作用超越了免疫调节,扩展到瘤发育和血管平衡,使其成为重要的治疗点.
  • 免疫检查点抑制剂 (ICI),与免疫相关的不良事件 (irAEs) 和心血管并发症之间的关联强调了需要阐明SHP2在这些过程中的功能.

研究的目的:

  • 审查关于SHP2/PTPN11生物学的当前知识,其参与免疫调节,癌症和血管平衡.
  • 讨论针对SHP2途径的新兴治疗策略,特别是与ICI结合使用.
  • 探索SHP2在不同细胞环境中的上下文依赖和对立的信号作用.

主要方法:

  • 文献综述和综合现有关于SHP2功能的研究.
  • 分析SHP2在免疫细胞 (T细胞) 和非免疫细胞 (内皮细胞,骨髓细胞,血管光滑肌细胞) 中的作用.
  • 检查SHP2信号响应各种刺激,包括PD-1/PD-L1,氧化应激,辐射和Notch-Jag1信号.

主要成果:

  • SHP2在T细胞中传递PD-1介导的抑制信号,是改善ICI疗效的目标.
  • 在正常情况下,SHP2促进血管平衡,并抑制内皮细胞和骨髓细胞的炎症.
  • SHP2表现出取决于环境的相反作用:在氧化应激下促进炎症,但在辐射后增加纤维化;在血管光滑肌细胞中起益动脉生成作用.

结论:

  • SHP2的双重信号传导能力显著调节免疫和血管系统的反应,受氧化还原状态,细胞类型和亚细胞区的影响.
  • 用ICI准SHP2是一种有前途的策略,可以克服ICI耐药性并增强抗瘤活性.
  • 进一步的研究对于减轻SHP2相关的心血管毒性至关重要,特别是在接受ICI治疗的患者中.